Keys to a Successful Exit: What do Strategics really value and which startups succeed

John Groetelaars was the CEO of Hillrom until its acquisition by Baxter for $12B in 2022. Throughout John’s career he has held leadership positions at BD, Bard, Boston Scientific, Ventrica and Guidant. Through his career he has led or contributed to over 60 strategic acquisitions and several divestitures, he shares his views on why some startups ‘get to YES’ with strategics, while others fail. He has seen early stage companies appropriately ‘work the org chart’ to get to decision makers for initial investments, ongoing updates and ultimately successful exits.
With a background spanning from the Boardroom with both public and Private Equity, to CEO and Venture Partner, we highly encourage you to help create a mindset and an understanding that can propel your company's success. John is currently a Venture Partner with Arborteum Ventures, is on the Board of Parexel and NavvSystems and will become Chair of the Board for Zeus. He brings his candid conversation and perspectives from having spent 30+ years in MedTech.
Key Take Aways:
- How to generate Strategic Interest?
- What is core to a product offering that would make it enticing to a strategic investor?
- What to expect in the lifecycle of a deal?
- Why some deals were successful while others weren’t?
- How to broaden outside of an R&D investment and get to the business leaders.